<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795687</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-MAE-2020-12</org_study_id>
    <nct_id>NCT04795687</nct_id>
  </id_info>
  <brief_title>Discovering Patterns in the Gut Microbiota Associated With the Risk of Stroke and the Outcome After a Stroke and Integration of These Data With Genomic Information to Find New Drug Targets and New Treatments to Improve Neurological Evolution and Functional Status of Stroke Patients.</brief_title>
  <acronym>MAESTRO</acronym>
  <official_title>Association of Metagenomics and Transcriptomics With the Appearance and Evolution of an Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The composition of the intestinal microbiota is associated with the risk of stroke and with&#xD;
      post-stroke neurological evolution. At the same time, the genetics and epigenetics of each&#xD;
      patient are associated with the composition of the intestinal microbiota. The study of the&#xD;
      microbiome in stroke patients will allow finding new therapeutic targets for the treatment of&#xD;
      stroke patients.&#xD;
&#xD;
      For the study, samples will be collected from those patients with ischemic stroke who come to&#xD;
      the hospital while the study is being carried out, taking into account certain criteria: the&#xD;
      patients must be over 18 years of age, have suffered an ischemic stroke (demonstrated by&#xD;
      resonance or head CT), not have any additional serious illness or unstable medical condition,&#xD;
      and not be included in clinical trials with neuroprotective drugs. On the other hand, the&#xD;
      control group will be asymptomatic, and will be made up of people who have not previously&#xD;
      suffered a stroke or a cardiovascular event and who do not have diseases that affect the&#xD;
      digestive tract.&#xD;
&#xD;
      The main variables of the study are the risk of stroke and disability after a cerebrovascular&#xD;
      accident (measured by mRS at 3rd month). Microbiota, genetic and epigenetic variables are&#xD;
      also taken into account, such as the presence and levels of bacteria, dysbiosis, genetic&#xD;
      polymorphisms and levels of methylation in CpG islands.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of stroke and disability after a stroke</measure>
    <time_frame>3 months</time_frame>
    <description>Use of the Modified Rankin Scale (mRS), evaluted from 0 to 6 (where higher scores mean worse outcome), to asses disability in patients who have suffered a stroke and comparison over time to check for recovery and degree of continued disability</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Ischemic stroke patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples and fecal samples stored with ethanol 96%.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Samples will be collected from those patients with ischemic stroke who attend the Hospital&#xD;
        de la Santa Creu i Sant Pau while the study is carried out.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ischemic stroke (demonstrated by resonance or head CT).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years of age.&#xD;
&#xD;
          -  Additional serious illness or unstable medical condition.&#xD;
&#xD;
          -  Inclusion in clinical trials with neuroprotective drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Israel Fernández Cadenas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miquel Lledós, MSc</last_name>
    <phone>+34679815196</phone>
    <email>mlledos@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Recerca Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miquel Lledós, MSc</last_name>
      <phone>+34679815196</phone>
      <email>mlledos@santpau.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gut microbiota</keyword>
  <keyword>Stroke</keyword>
  <keyword>Metagenomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected individual participant data (IPD).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Starting 6 months after publication.</ipd_time_frame>
    <ipd_access_criteria>IPD will be shared for further analysis under request. Requests will be reviewed by the overall study official Dr. Israel Fernández Cadenas.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

